文章：

沙妥珠单抗戈维替康联合姑息性放疗的安全性及有效性——一项回顾性多中心队列研究

The Safety and Efficacy of the Combination of Sacituzumab Govitecan and Palliative Radiotherapy—A Retrospective Multi-Center Cohort Study

原文发布日期：25 April 2024

DOI: 10.3390/cancers16091649

类型: Article

开放获取: 是

英文摘要：

Sacituzumab govitecan (SG) is a new treatment option for patients with metastatic triple-negative and hormone receptor-positive, HER2-negative breast cancer. This antibody–drug conjugate is currently approved as monotherapy. Palliative radiotherapy is frequently used to treat symptomatic metastases locally. Concurrent use of SG and irradiation was excluded in clinical trials of SG, and there are currently limited published data. We report here a systematic review, as well as a retrospective multi-center study of 17 patients with triple-negative breast cancer who received concurrent SG and radiotherapy. In these patients, concurrent use was found to be efficient, safe and well tolerated. There were no apparent differences in moderate or severe acute toxicity according to the timing of SG administration.

摘要翻译： 

Sacituzumab govitecan（SG）是转移性三阴性及激素受体阳性、HER2阴性乳腺癌患者的新型治疗选择。该抗体偶联药物目前获批作为单药治疗方案。姑息性放疗常用于局部治疗症状性转移灶。在SG的临床试验中排除了SG与放疗的联合应用，目前公开发表的相关数据有限。本文报道一项系统性综述，以及对17例接受SG与放疗同步治疗的三阴性乳腺癌患者进行的回顾性多中心研究。结果显示，在这些患者中同步治疗方案有效、安全且耐受性良好。根据SG给药时机的不同，中重度急性毒性反应未见明显差异。

原文链接：

The Safety and Efficacy of the Combination of Sacituzumab Govitecan and Palliative Radiotherapy—A Retrospective Multi-Center Cohort Study